Back to Search
Start Over
Neuroprotective Effects of rhGLP-1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury.
- Source :
-
Drug Development Research . May2016, Vol. 77 Issue 3, p124-133. 10p. - Publication Year :
- 2016
-
Abstract
- Preclinical Research The aim of the present study was to evaluate the neuroprotective benefits of rhGLP ‐ 1 in diabetic rats subjected to acute cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion/reperfusion (MCAO/R). Streptozotocin (STZ) ‐ induced diabetic rats were pretreated with rhGLP ‐ 1 (10, 20, or 40 μg/kg ip, tid) for 14 days. During this time, body weight and fasting blood glucose levels were assessed. Rats were then subjected to MCAO 90 min/R 24 h. At 2 and 24 h of reperfusion, rats were evaluated for neurological deficits and blood samples were collected to analyze markers of brain injury. Rats were then sacrificed to assess the infarction volume. rhGLP ‐ 1 pretreatment lowered blood glucose levels, improved neurological scores, attenuated infarct volumes, and reduced the blood levels of S100 calcium ‐ binding protein B (S100B), neuron ‐ specific enolase (NSE), and myelin basic protein (MBP). rhGLP ‐ 1 has neuroprotective benefits in diabetic rats with cerebral ischemia/reperfusion injury and could potentially be used as a prophylatic neuroprotectant in diabetic patients at high risk of ischemic stroke. Drug Dev Res 77 : 124 – 133, 2016. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02724391
- Volume :
- 77
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Drug Development Research
- Publication Type :
- Academic Journal
- Accession number :
- 114818371
- Full Text :
- https://doi.org/10.1002/ddr.21297